A growing interest currently surrounds the Relationship between persistent COVID and similar diseases in cats, especially following the results of a study conducted by the University of California, Davis. This study has shed light on how certain therapies, already used in veterinary medicine, could be used to better understand and address the immunological complications that occur after prolonged infection in both cats and humans. The parallelism between both species This is surprising and is generating new hope for the development of innovative treatments.
In recent years, the feline infectious peritonitis (FIP) It has been analyzed as a model for researching the behavior of serious viral infections. Despite affecting cats exclusively, the study of this feline coronavirus has become a valuable tool for understanding the Long-term COVID and its effects on the immune system of human beings.
Similarities between feline FIP and persistent COVID
FIP occurs when feline coronavirus, which normally causes only mild digestive discomfort, undergoes changes caused by various genetic or environmental factors. This allows it to attack immune cells and spread through the body, resulting in two variants: the wet form, with fluid accumulation in the abdomen or thorax, and the dry form, which causes internal damage without such accumulation. In both cases, cats develop generalized inflammation, fever and deterioration of several organs, along with a significant loss of key immune cells.
About 2% of cats suffer from this disease., especially younger animals living in shelters or breeding facilities. Although the development of a specific antiviral (GS-441524) has increased life expectancy, some animals that survive the virus still present enlarged or swollen lymph nodes, a sign that your immune system continues to be overstimulated for a long time, very similar to what happens with .
Scientists observed that even after the virus was eliminated, these “immune aftereffects” persisted. This prolonged immune response In cats, it has allowed us to identify biological patterns similar to those of COVID that persist after the acute phase in humans.
Stem cell therapy: enhancing immune recovery
To address these complications, the UC Davis team designed a combination therapy with antiviral drugs and mesenchymal stem cells (MSC)These cells, usually extracted from bone marrow, have the ability to regenerate various tissues and modulate the immune system's response.
During the study, two groups of cats were treated with FIP: one received only the antiviral and the other, in addition to this drug, received MSC infusions. Experts reported that all cats survived, but among those treated with stem cells, the immune restoration was much more evidentIn particular, they showed a decrease in hyperactive lymphocytes responsible for immune overload, and an increase in the number of regulatory T lymphocytes, which are responsible for balancing the immune response and preventing secondary damage to the body.
According to the results, animals treated with MSC also presented fewer signs of residual inflammation and an immune system closer to normal. This finding suggests the possibility that the therapy could promote the formation of long-term memory immune cells, which could protect against future infections and similar complications.
El treatment is considered safe and no serious adverse effects have been recorded during the trial, increasing its interest in its potential application in humans with persistent COVID.
Veterinary medicine, key to translational science
Researchers emphasize the importance of studying animal diseases that share characteristics with human disorders, as this can speed up the development of new therapies without the need to wait for long periods of research exclusively in people. The case of FIP as a model for understanding the veterinary and human medicine can feed back into each other.
Professor Amir Kol, one of the lead authors of the study, stresses that Many domestic animals suffer from ailments similar to those of humans., and that applying this knowledge can have a significant impact on both pets and their owners.
The possibility of translating results into new treatments for persistent COVID could accelerate the development of therapeutic options to alleviate the immune-mediated side effects that affect so many people around the world.
As the research progresses, the idea is reinforced that comparable diseases in different mammals can facilitate the finding of common solutions, opening a faster and safer path to more effective medicines and recovery systems.
The latest findings in cats are serving as a basis for exploring innovative approaches to treating long-term COVID, thanks to evidence that the immune system can be more effectively restored through targeted cell therapies.
The recent advance in the management of feline infectious peritonitis not only represents hope for affected cats, but also provides valuable insights into the nature of persistent COVID in humans. The study highlights the potential of cell therapies in immune regulation and demonstrates the usefulness of animal models to accelerate scientific progress for the benefit of both species.
